This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
moving-average-crossover: Archive
Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NRIXPositive Net Change EYPTPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ATRAPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Xcel (XEL) Moves 6.7% Higher: Will This Strength Last?
by Zacks Equity Research
Xcel (XEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
XELPositive Net Change FEPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Immunome (IMNM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IMNMNegative Net Change DTILNo Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Savers Value (SVV) Surges 5.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Savers Value (SVV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SVVNegative Net Change SGCPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?
by Zacks Equity Research
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
QURENegative Net Change TGTXPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ZVRAPositive Net Change NKTRPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Daqo (DQ) Surges 14.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Daqo (DQ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
DQPositive Net Change MTXNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Intrepid Potash (IPI) Soars 8.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Intrepid Potash (IPI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IPIPositive Net Change NTRPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Procore Technologies (PCOR) Surges 5.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Procore Technologies (PCOR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PCORNegative Net Change QBTSNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today